NEW YORK, March 5, 2014 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts Review released its analysts' notes regarding Illumina, Inc. (NASDAQ:ILMN), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Medtronic, Inc. (NYSE: MDT), Sirona Dental Systems, Inc. (NASDAQ: SIRO), and NPS Pharmaceuticals, Inc. (NASDAQ: NPSP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Illumina, Inc. Analyst Notes
On February 24, 2014, Illumina, Inc. (Illumina) reported that its Illumina Genome Network (IGN) the Sweden-based Science for Life Laboratory (SciLifeLab) has joined IGN to provide researchers with wider access to Illumina's whole genome sequencing technology. SciLifeLab is the first IGN partner in Europe and will initiate a national large-scale population sequencing program seeking to identify genetic causes of human diseases. According to Illumina, IGN links researchers needing large-scale, whole human genome sequencing with world class institutions that provide this service, and delivers unmatched access to the highest quality of whole genome sequencing data. Commenting on the news, Joakim Lundeberg, Professor in Gene Technology at KTH Royal Institute of Technology and Director of the National Genomics Infrastructure at Science for Life Laboratory, said, "We now have the opportunity to offer an even larger capacity of high throughput sequencing to researchers from all over Sweden. In the research program we are about to launch, we aim to sequence more than 1,000 human genomes using the Illumina systems." The full analyst notes on Illumina, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03052014/ILMN/report.pdf
--
Alexion Pharmaceuticals, Inc. Analyst Notes
On March 3, 2014, Alexion Pharmaceuticals, Inc. (Alexion) announced that it has received acknowledgement from the National Institute for Health and Clinical Excellence (NICE) for eculizumab (Soliris®) as a very effective treatment option for patients with aHUS, and that the use of eculizumab would be of significant value to patients with this life-threatening disorder who have no other treatment options. Alexion also stated that the positive NICE assessment aligns with the two prior positive recommendations from Government - AGNSS and NHS England. In addition, NICE confirmed that the broad interim NHS England commissioning policy for eculizumab treatment of existing and new patients with aHUS will continue. The full analyst notes on Alexion Pharmaceuticals, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03052014/ALXN/report.pdf
--
Medtronic, Inc. Analyst Notes
On March 3, 2014, Medtronic, Inc. (Medtronic) announced that in collaboration with Aetna, it will work with doctors in a new program to reach up to 300 fully insured members with uncontrolled type 2 diabetes who may improve their health using insulin pump therapy. "We want to help members with type 2 diabetes to enjoy a more flexible lifestyle and have better glucose control. Improving education and assistance for those learning to use insulin pumps may help increase consideration and successful use of a proven therapy that can help them achieve these goals," said Ed Pezalla, M.D., Aetna's national medical director for pharmacy policy and strategy. "We also are excited to create value-based arrangements with companies like Medtronic who are ready to share accountability for the role their products and services play in improving members' health." Medtronic further announced that eligible members will receive targeted education, case management and other patient support to help control blood sugar, which also may lower their health care costs. Information gathered from the program is also expected to help doctors and other health care providers more easily identify and support those who can benefit most from this therapy. The full analyst notes on Medtronic, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03052014/MDT/report.pdf
--
Sirona Dental Systems, Inc. Analyst Notes
According to Sirona Dental Systems, Inc. (Sirona) website's events page, the Company is scheduled to participate in the upcoming Dental South China 2014 International Expo at the Pazhou Complex in Guangzhou, China. The expo will run from March 6, 2014 to March 9, 2014. The full analyst notes on Sirona Dental Systems, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03052014/SIRO/report.pdf
--
NPS Pharmaceuticals, Inc. Analyst Notes
On February 26, 2014, NPS Pharmaceuticals, Inc. (NPS Pharmaceuticals) announced that it will present at the upcoming Barclays Global Healthcare Conference in Miami, Florida on Tuesday, March 11, 2014 at 9:00 a.m. ET. The presentation will be available as a live webcast with a replay available approximately three hours after the presentation has concluded. Interested parties may log on to NPS Pharmaceutical's website to access the webcast. The full analyst notes on NPS Pharmaceuticals, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03052014/NPSP/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review